224 related articles for article (PubMed ID: 33797608)
1. Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
Liu J; Hao J; Niu Y; Wu X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2079-2092. PubMed ID: 33797608
[TBL] [Abstract][Full Text] [Related]
2. Network pharmacology dissection of multiscale mechanisms of herbal medicines in stage IV gastric adenocarcinoma treatment.
Gao L; Hao J; Niu YY; Tian M; Yang X; Zhu CH; Ding XL; Liu XH; Zhang HR; Liu C; Qin XM; Wu XZ
Medicine (Baltimore); 2016 Aug; 95(35):e4389. PubMed ID: 27583849
[TBL] [Abstract][Full Text] [Related]
3. Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.
Mao Y; Hao J; Jin ZQ; Niu YY; Yang X; Liu D; Cao R; Wu XZ
Oncotarget; 2017 Apr; 8(16):27007-27021. PubMed ID: 28212580
[TBL] [Abstract][Full Text] [Related]
4. Network Pharmacology-Based and Clinically Relevant Prediction of the Potential Targets of Chinese Herbs in Ovarian Cancer Patients.
Sun J; Liu J; Liu D; Wu X
Biomed Res Int; 2020; 2020():8965459. PubMed ID: 33150184
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology.
Zhu H; Hao J; Niu Y; Liu D; Chen D; Wu X
Sci Rep; 2018 May; 8(1):7238. PubMed ID: 29740162
[TBL] [Abstract][Full Text] [Related]
6. Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology.
Bing Z; Cheng Z; Shi D; Liu X; Tian J; Yao X; Zhang J; Wang Y; Yang K
BMC Complement Altern Med; 2018 Nov; 18(1):293. PubMed ID: 30400936
[TBL] [Abstract][Full Text] [Related]
7. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
[TBL] [Abstract][Full Text] [Related]
8. Conventional treatment integrated with Chinese herbal medicine improves the survival rate of patients with advanced non-small cell lung cancer.
Wang CY; Huang HS; Su YC; Tu CY; Hsia TC; Huang ST
Complement Ther Med; 2018 Oct; 40():29-36. PubMed ID: 30219465
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and pharmacological mechanisms of Chinese herbal medicine for coronary heart disease complicated with heart failure.
Teng Y; Li Y; Wang L; Wang B; Su S; Chen J; Lu Z; Zhu H; Zhao M
J Ethnopharmacol; 2024 Mar; 322():117605. PubMed ID: 38128892
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of combined conventional medicine and Chinese herbal medicine decreases the mortality risk of patients with lung cancer.
Yeh MH; Wu HC; Lin NW; Hsieh JJ; Yeh JW; Chiu HP; Wu MC; Tsai TY; Yeh CC; Li TM
Complement Ther Med; 2020 Aug; 52():102427. PubMed ID: 32951705
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan.
Li TM; Yu YH; Tsai FJ; Cheng CF; Wu YC; Ho TJ; Liu X; Tsang H; Lin TH; Liao CC; Huang SM; Li JP; Lin JC; Lin CC; Liang WM; Lin YJ
J Ethnopharmacol; 2018 Mar; 213():92-100. PubMed ID: 29100936
[TBL] [Abstract][Full Text] [Related]
12. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
[TBL] [Abstract][Full Text] [Related]
13. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
14. Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology.
Gao L; Wang XD; Niu YY; Duan DD; Yang X; Hao J; Zhu CH; Chen D; Wang KX; Qin XM; Wu XZ
Sci Rep; 2016 May; 6():24944. PubMed ID: 27143508
[TBL] [Abstract][Full Text] [Related]
15. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
[TBL] [Abstract][Full Text] [Related]
16. Uncovering Active Ingredients and Mechanisms of Spica Prunellae in the Treatment of Colon Adenocarcinoma: A Study Based on Network Pharmacology and Bioinformatics.
Lei Y; Yuan H; Gai L; Wu X; Luo Z
Comb Chem High Throughput Screen; 2021; 24(2):306-318. PubMed ID: 32748741
[TBL] [Abstract][Full Text] [Related]
17. The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.
Chen SL; Lin WC; Chen YC; Chen JL; Wu YH; Yang SH; Chen HY
Front Pharmacol; 2022; 13():1018281. PubMed ID: 36278218
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive Traditional Chinese Medicine Improves Survival in Patients With Advanced Lung Adenocarcinoma Treated With First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): A Nationwide, Population-Based Cohort Study.
Li CL; Hsia TC; Li CH; Chen KJ; Yang YH; Yang ST
Integr Cancer Ther; 2019; 18():1534735419827079. PubMed ID: 30836771
[TBL] [Abstract][Full Text] [Related]
19. Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor.
Kwon BS; Cho YH; Yoon SK; Lee DH; Kim SW; Kwon DH; Lee JC; Choi CM
Thorac Cancer; 2020 Feb; 11(2):436-442. PubMed ID: 31910497
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
